Circulating tumour DNA Assessment of PIK3CA to guide Treatment Response - A phase II randomised study to evaluate alpelisib plus fulvestrant versus capecitabine in oestrogen receptor positive, HER2-negative advanced breast cancer patients with PIK3CA mutant circulating DNA

  • McCartney, Amelia (Primary Chief Investigator (PCI))

Project: Research

Project Details

AcronymCAPTURE
StatusActive
Effective start/end date4/06/20 → 3/06/25

Keywords

  • clinical trial
  • phase 2 study
  • treatment efficacy
  • treatment safety